PharmaTelevision Spotlights Aptalis' Year in Review

FDA approvals, revenue gain, and organic business growth are just a few of the topics that John Fraher, President, Aptalis Pharma, addresses during an on-air interview with Fintan Walton, CEO, PharmaVentures and PharmaTelevision. The interview, conducted during BIO 2012 in Boston, reflects Mr. Fraher’s commentary regarding the integration of companies post Axcan Intermediate Holdings’ acquisition of Eurand N.V. in 2011. The interview is available via on-demand at PharmaTelevision and will also be available to the public at the Aptalis Pharmaceutical Technologies website www.AptalisPharmaTech.com. Mr. Fraher serves a key role in setting strategic direction for Aptalis with specific oversight of the company’s Pharmaceutical Technologies and Global Supply Chain business unit.

Approximately 1 year ago PharmaTelevison conducted its first interview with Mr. Fraher just a few months after Axcan completed its acquisition of Eurand N.V. During the months following the acquisition, the companies completed their integration while realizing several major milestones, including FDA approvals, the in-licensing of a number of products, and a closing-year revenue of $470 million – a significant increase on the prior year. During his BIO 2012 interview with PharmaTelevision, Mr. Fraher discusses these milestones and the company’s strategic direction moving forward. Aptalis Pharma Inc. is a privately held, leading specialty pharmaceutical company providing innovative, effective therapies for unmet medical needs, including cystic fibrosis and gastrointestinal disorders. Aptalis, formed from the recent combination of Axcan Pharma and Eurand, has manufacturing and commercial operations in the United States, the European Union, and Canada, and its products include ZENPEP, CANASA, CARAFATE, PYLERA, LACTEOL, DELURSAN, PANZYTRAT, and SALOFALK. Aptalis also formulates and clinically develops enhanced pharmaceutical and biopharmaceutical products for itself and others using its proprietary technology platforms, including bioavailability enhancement of poorly soluble drugs, custom-release profiles, and taste-masking/orally disintegrating tablet (ODT) formulations.

Aptalis Pharmaceutical Technologies, formerly known as Eurand Pharmaceutical Technologies, offers a broad portfolio of oral drug delivery technology platforms: Customized Drug Release, Bioavailability Enhancement, and Taste Masking for ODTs, and other dosage forms. Together, these technology platforms combined with licensing, manufacturing, and R&D capabilities enable Aptalis Pharmaceutical Technologies to produce customized drug formulation solutions for partners across a range of dosage forms and therapies with high patient acceptability. Aptalis Pharmaceutical Technologies will continue to develop and manufacture products for its partners, as well as support the drug development process for the Aptalis Pharma pipeline and portfolio of products.